Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M141Revenue $M15.6Net Margin (%)-126.7Z-Score1.5
Enterprise Value $M138EPS $-0.2Operating Margin %-202.4F-Score1
P/E(ttm))0Cash Flow Per Share $0Pre-tax Margin (%)-138.2Higher ROA y-yN
Price/Book2.610-y EBITDA Growth Rate %0Quick Ratio3.9Cash flow > EarningsN
Price/Sales11.05-y EBITDA Growth Rate %48.4Current Ratio5.6Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-17.8Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-30.4Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M75.0ROI % (ttm)-45.5Gross Margin Increase y-yN

Gurus Latest Trades with NEPT

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found!

NEPT is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


NEPT: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Montgomery, Adrian TaylorDirector 2014-12-03Buy11,000$2.21-14.93view
Moretz, John MorrisDirector 2014-11-25Buy31,382$2.09-10.05view
Moretz, John MorrisDirector 2014-11-24Buy68,188$2.15-12.56view
Lemieux, PierreDirector or Senior Officer of Insider or Subsidiar 2014-11-12Buy5,000$2.19-14.16view
Godin, AndréSenior Officer 2014-11-12Buy3,000$2.15-12.56view
Ripplinger, JohnSenior Officer 2014-11-11Buy3,550$2.12-11.32view
Turcotte, MarioSenior Officer 2014-11-11Buy6,870$2.14-12.15view
Godin, AndréSenior Officer 2014-11-11Buy8,000$2.12-11.32view
Fitzgibbon, PierreDirector 2014-11-10Buy37,500$2.09-10.05view
Huart, BenoîtDirector 2014-11-10Buy7,000$2.03-7.39view

Press Releases about NEPT :

    Quarterly/Annual Reports about NEPT:

      News about NEPT:

      Articles On GuruFocus.com
      What Drives St. Jude Medical to Be More Diversified? Apr 30 2014 


      More From Other Websites
      Why Neptune Technologies & Bioressources, Inc. (NEPT) Could Shock the Market Soon - Tale of the Tape Mar 03 2015
      Neptune to Present at 27th Annual Roth Conference Mar 02 2015
      Acasti Receives Full Data for Phase II TRIFECTA Trial Mar 02 2015
      NeuroBioPharm Receives Final Court Approval and Completes Arrangement With Neptune Feb 20 2015
      Why Neptune Technologies & Bioressources (NEPT) Could Be Positioned for a Surge? - Tale of the Tape Feb 18 2015
      NeuroBioPharm's Shareholders Approve Arrangement With Neptune Feb 12 2015
      Should Neptune Technologies & Bioressources (NEPT) Be On Your Radar Now? - Tale of the Tape Feb 10 2015
      Dr. Tina Sampalis Appointed Medical Science Liaison for Neptune Feb 05 2015
      Jim Hamilton Officially Starts at Neptune Feb 03 2015
      Acasti Announces Third Quarter Results Jan 13 2015
      Neptune Announces Third Quarter Results Jan 13 2015
      NeuroBioPharm to be Privatized by Neptune - Enters Into Arrangement Agreement With Neptune and... Jan 13 2015
      5 Earnings Short-Squeeze Plays: Neptune Technologies and More Jan 13 2015
      Neptune to Present at OneMedForum Jan 08 2015
      Neptune to Hold Conference Call to Discuss Third Quarter Results Jan 06 2015
      Neptune Completes Plant Ramp-Up Dec 03 2014
      Jim Hamilton Appointed President & CEO of Neptune Dec 03 2014
      Neptune Receives TSX Approval For Normal Course Issuer Bid Oct 30 2014
      Activist George Haywood Reveals New Biotech Target Oct 28 2014
      Neptune and BlueOcean Sign Licensing Agreement Oct 20 2014
      Neptune Announces Normal Course Issuer Bid Oct 16 2014
      Neptune Announces Second Quarter Results – Shipments of NKO® Underway Oct 16 2014
      Neptune to Hold Conference Call to Discuss Second Quarter Results Oct 16 2014
      Short-term bulls diving for Neptune Sep 16 2014
      Why Neptune Technologies (NEPT) Could Be Positioned for a Slump Jul 30 2014
      Has Enzymotec Been Over-Punished? Jun 09 2014
      NEPTUNE TECHNOLOGIES & BIORESSOURCES INC. Financials Jun 06 2014
      Neptune, Acasti and NeuroBioPharm Announce Litigation Regarding its Former Chief Executive Officer May 30 2014
      High option volume stocks May 28 2014
      Enzymotec Ltd. Provides Update on Patent Litigation With Neptune Apr 01 2014

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK